285 related articles for article (PubMed ID: 33940348)
1. Metastatic small bowel adenocarcinoma: role of metastasectomy and systemic chemotherapy.
Bhamidipati D; Colina A; Hwang H; Wang H; Katz M; Fournier K; Serpas V; Thomas J; Sun R; Wolff RA; Raghav K; Overman MJ
ESMO Open; 2021 Jun; 6(3):100132. PubMed ID: 33940348
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma.
Overman MJ; Kopetz S; Wen S; Hoff PM; Fogelman D; Morris J; Abbruzzese JL; Ajani JA; Wolff RA
Cancer; 2008 Oct; 113(8):2038-45. PubMed ID: 18759326
[TBL] [Abstract][Full Text] [Related]
3. Treatment of peritoneal metastases from small bowel adenocarcinoma.
Rovers KP; de Bree E; Yonemura Y; de Hingh IH
Int J Hyperthermia; 2017 Aug; 33(5):571-578. PubMed ID: 27919181
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy in advanced small bowel adenocarcinoma.
Locher C; Malka D; Boige V; Lebray P; Elias D; Lasser P; Ducreux M
Oncology; 2005; 69(4):290-4. PubMed ID: 16282708
[TBL] [Abstract][Full Text] [Related]
5. Second-line Chemotherapy for Previously Treated Metastatic Small Bowel Adenocarcinoma: A Retrospective Analysis.
Nakazawa T; Narita Y; Kumanishi R; Ogata T; Matsubara Y; Nozawa K; Kato K; Honda K; Masuishi T; Bando H; Kadowaki S; Ando M; Hara K; Tajika M; Muro K
Anticancer Res; 2021 Oct; 41(10):5147-5155. PubMed ID: 34593466
[TBL] [Abstract][Full Text] [Related]
6. Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study.
Legué LM; van Erning FN; Bernards N; Lemmens VEPP; de Hingh IHJT; Creemers GJ
Target Oncol; 2019 Dec; 14(6):699-705. PubMed ID: 31625001
[TBL] [Abstract][Full Text] [Related]
7. Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater.
Gulhati P; Raghav K; Shroff R; Varadhachary G; Javle M; Qiao W; Wang H; Morris J; Wolff R; Overman MJ
Oncologist; 2018 Mar; 23(3):277-e26. PubMed ID: 29259073
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological features and treatment outcomes of metastatic or locally unresectable small bowel adenocarcinoma.
Li X; Ying H; Cheng Y; Zhao L; Zhao S; Bai C; Zhou J
J BUON; 2019; 24(6):2539-2545. PubMed ID: 31983130
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology (ASMO).
Aydin D; Sendur MA; Kefeli U; Umut Unal O; Tastekin D; Akyol M; Tanrikulu E; Ciltas A; Bala Ustaalioglu B; Sener Dede D; Esbag O; Inal A; Bilir C; Bilici A; Harputlu H; Berk V; Sevinc A; Yildirim Ozdemir N; Yildirim E; Sonkaya A; Ali Ustaoglu M; Gumus M
J BUON; 2016; 21(5):1242-1249. PubMed ID: 27837629
[TBL] [Abstract][Full Text] [Related]
10. Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy.
Tsushima T; Taguri M; Honma Y; Takahashi H; Ueda S; Nishina T; Kawai H; Kato S; Suenaga M; Tamura F; Morita S; Boku N
Oncologist; 2012; 17(9):1163-70. PubMed ID: 22622149
[TBL] [Abstract][Full Text] [Related]
11. Natural history and prognostic factors for localised small bowel adenocarcinoma.
Colina A; Hwang H; Wang H; Katz MHG; Sun R; Lee JE; Thomas J; Tzeng CW; Wolff RA; Raghav K; Overman MJ
ESMO Open; 2020 Nov; 5(6):e000960. PubMed ID: 33188051
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for small-bowel Adenocarcinoma at a single institution.
Suenaga M; Mizunuma N; Chin K; Matsusaka S; Shinozaki E; Oya M; Ueno M; Yamaguchi T; Muto T; Konishi F; Hatake K
Surg Today; 2009; 39(1):27-31. PubMed ID: 19132464
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy for patients with unresectable or metastatic small bowel adenocarcinoma: a systematic review.
Nishikawa Y; Hoshino N; Horimatsu T; Funakoshi T; Hida K; Sakai Y; Muto M; Nakayama T
Int J Clin Oncol; 2020 Aug; 25(8):1441-1449. PubMed ID: 32448950
[TBL] [Abstract][Full Text] [Related]
14. Novel Prognostic Factors in Resected Small Bowel Adenocarcinoma.
Huffman BM; Jin Z; Yadav S; Patel S; Nagorney DM; Truty MJ; McWilliams RR; Halfdanarson TR; Mahipal A
Clin Colorectal Cancer; 2019 Sep; 18(3):218-225. PubMed ID: 31178274
[TBL] [Abstract][Full Text] [Related]
15. Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study.
Aparicio T; Svrcek M; Zaanan A; Beohou E; Laforest A; Afchain P; Mitry E; Taieb J; Di Fiore F; Gornet JM; Thirot-Bidault A; Sobhani I; Malka D; Lecomte T; Locher C; Bonnetain F; Laurent-Puig P
Br J Cancer; 2013 Dec; 109(12):3057-66. PubMed ID: 24196786
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy in small bowel adenocarcinoma: 10-year experience of the British Columbia Cancer Agency.
Czaykowski P; Hui D
Clin Oncol (R Coll Radiol); 2007 Mar; 19(2):143-9. PubMed ID: 17355111
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): the Royal Marsden Hospital (RMH) experience.
Khan K; Peckitt C; Sclafani F; Watkins D; Rao S; Starling N; Jain V; Trivedi S; Stanway S; Cunningham D; Chau I
BMC Cancer; 2015 Jan; 15():15. PubMed ID: 25603878
[TBL] [Abstract][Full Text] [Related]
18. Palliative chemotherapy for patients with synchronous metastases of small-bowel adenocarcinoma: A reflection of daily practice.
Legué LM; Bernards N; Lemmens VE; de Hingh IH; Creemers GJ; van Erning FN
United European Gastroenterol J; 2019 Dec; 7(10):1380-1388. PubMed ID: 31839964
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Prognostic Factors and Adjuvant Chemotherapy in Patients With Small Bowel Adenocarcinoma Who Underwent Curative Resection.
Aydin D; Sendur MA; Kefeli U; Unal OU; Tastekin D; Akyol M; Tanrikulu E; Ciltas A; Ustaalioglu BB; Uysal M; Esbag O; Yazilitas D; Tanrıverdi O; Bilici A; Arpaci E; Berk V; Yetisyigit T; Ozdemir NY; Oztop I; Alacacioglu A; Aydin O; Ozcelik M; Yildirim E; Dinc N; Gumus M
Clin Colorectal Cancer; 2017 Sep; 16(3):220-227. PubMed ID: 27670893
[TBL] [Abstract][Full Text] [Related]
20. Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer.
Takayoshi K; Kusaba H; Uenomachi M; Mitsugi K; Makiyama C; Makiyama A; Uchino K; Shirakawa T; Shibata Y; Shinohara Y; Inadomi K; Tsuchihashi K; Arita S; Ariyama H; Esaki T; Akashi K; Baba E
Cancer Chemother Pharmacol; 2017 Aug; 80(2):333-342. PubMed ID: 28653251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
